NasdaqCM - Nasdaq Real Time Price USD
Curis, Inc. (CRIS)
As of 2:40 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -1.84 | -1.63 | -7.21 | -4.57 |
| Low Estimate | -2.11 | -2.09 | -8.29 | -8.47 |
| High Estimate | -1.62 | -0.94 | -5.18 | -2.34 |
| Year Ago EPS | -2.13 | -2.03 | -8.96 | -7.21 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 2.28M | 2.33M | 9.32M | 8.78M |
| Low Estimate | -- | -- | 5M | -- |
| High Estimate | 3.4M | 3.4M | 11.4M | 12M |
| Year Ago Sales | 2.83M | 2.7M | 10.02M | 9.32M |
| Sales Growth (year/est) | -19.50% | -13.60% | -7.00% | -5.80% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -2.33 | -2.11 | -2.12 | -1.67 |
| EPS Actual | -2.13 | -2.03 | -2.05 | -2.03 |
| Difference | 0.2 | 0.08 | 0.07 | -0.36 |
| Surprise % | 8.60% | 3.80% | 3.30% | -21.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.84 | -1.63 | -7.21 | -4.57 |
| 7 Days Ago | -1.84 | -1.63 | -7.21 | -4.57 |
| 30 Days Ago | -1.84 | -1.63 | -7.21 | -4.57 |
| 60 Days Ago | -1.84 | -1.63 | -7.21 | -4.57 |
| 90 Days Ago | -1.5 | -1.31 | -6.15 | -4.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CRIS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 13.60% | -- | -- | 3.10% |
| Next Qtr. | 19.70% | -- | -- | 8.00% |
| Current Year | 19.50% | -- | -- | 2.30% |
| Next Year | 36.60% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -- | -- | -- | 11.85% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2024 |
| Maintains | Truist Securities: Buy to Buy | 5/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 5/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/9/2024 |
Related Tickers
RIGL Rigel Pharmaceuticals, Inc.
14.78
-0.20%
ONCT Oncternal Therapeutics, Inc.
1.7896
-14.37%
AGEN Agenus Inc.
4.4900
-0.22%
NERV Minerva Neurosciences, Inc.
2.4601
-1.60%
ATNM Actinium Pharmaceuticals, Inc.
1.8541
+4.16%
CYTK Cytokinetics, Incorporated
54.71
+1.67%
IKNA Ikena Oncology, Inc.
1.6800
-0.59%
TSHA Taysha Gene Therapies, Inc.
1.9650
-2.72%
ORMP Oramed Pharmaceuticals Inc.
2.3547
+0.63%
ALRN Aileron Therapeutics, Inc.
3.7979
+6.38%